Last reviewed · How we verify
Tauroursodeoxycholic Acid — Competitive Intelligence Brief
marketed
Bile acid derivative / Chemical chaperone
Endoplasmic reticulum stress pathways; TGR5 receptor (partial)
Neurology / Rare genetic disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
Tauroursodeoxycholic Acid (Tauroursodeoxycholic Acid) — Johns Hopkins University. Tauroursodeoxycholic acid (TUDCA) is a bile acid that reduces endoplasmic reticulum stress and promotes cell survival by stabilizing mitochondrial function and inhibiting apoptosis pathways.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tauroursodeoxycholic Acid TARGET | Tauroursodeoxycholic Acid | Johns Hopkins University | marketed | Bile acid derivative / Chemical chaperone | Endoplasmic reticulum stress pathways; TGR5 receptor (partial) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Bile acid derivative / Chemical chaperone class)
- Johns Hopkins University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tauroursodeoxycholic Acid CI watch — RSS
- Tauroursodeoxycholic Acid CI watch — Atom
- Tauroursodeoxycholic Acid CI watch — JSON
- Tauroursodeoxycholic Acid alone — RSS
- Whole Bile acid derivative / Chemical chaperone class — RSS
Cite this brief
Drug Landscape (2026). Tauroursodeoxycholic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/tauroursodeoxycholic-acid. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab